Full Breakdown
India’s Trade-Margin Cap on Cancer Drugs: Early Price Cuts and Persistent Gaps
By Drooid · · How we work
In this breakdown
01
Core Event – NPPA Implements 30% Trade-Margin Ceiling on 137 Non-Scheduled Cancer Medicines
On October 17 the National Pharmaceutical Pricing Authority (NPPA) issued an order limiting the trade margin that distributors, stockists and other intermediaries may add to the maximum retail price (MRP) of 137 non-scheduled anti-cancer drugs to 30 percent. The revised price list, reflecting company submissions up to October 27, will become effective on November 9. Manufacturers must report formulation-level details (brand, composition, pack size, price-to-stockist and revised MRP). The cap applies to patented, chemotherapy, targeted, immunotherapy, hormonal and blood-cancer medicines, but it does not directly lower the manufacturers’ selling price.
02
Background & Context – High Out-of-Pocket Burden and Prior Controls
Cancer drives the majority of catastrophic health spending in India, with out-of-pocket payments estimated at 50-80 % of direct treatment costs. Drugs account for over half of cancer-care expenses, forcing many patients to choose cheaper, less effective alternatives or abandon therapy. In 2019 the government capped trade margins on 42 anti-cancer drugs; the current order expands that regime.
Visual evidence
Images from the story
03
Official Statements & Responses – Government Rationale and Judicial Scrutiny
The government argues that limiting distributor and stockist mark-ups will curb excessive profit margins and pass savings to patients, estimating an annual reduction of INR2,500 crore in out-of-pocket spending. The NPPA notes that where the supply-chain markup was large, the 30 % ceiling yields steep price cuts; where manufacturers already price near the allowed maximum, the impact is limited.
The Supreme Court has intervened, questioning the disparity between the price a private hospital can charge for a cancer injection (? INR1.3 lakh) and the price a distributor pays (? INR11,000). The Court’s bench has reserved its order on a broader proposal to extend the trade-margin cap to all non-scheduled medicines, leaving the next steps uncertain.
04
Verbatim Quote
- “Any intervention to lower the prices of cancer drugs is a welcome step,” — Ms. Nadimpally
05
What’s Next – Pending Supreme Court Order and Potential Expansion of Margin Caps
The Supreme Court’s reserved order on a wider trade-margin cap introduces uncertainty about future regulatory scope. If endorsed, the 30 % ceiling could be applied to all non-scheduled medicines, affecting a larger segment of the pharmaceutical market. The NPPA has indicated that the revised list will be updated periodically, and manufacturers must seek prior permission before reducing production. The ultimate benefit to patients will depend on the brands prescribed, the extent to which hospitals pass on the lower MRPs, and any additional policy measures—such as compulsory licensing or reforms to PAP exclusions—implemented in response to advocacy concerns.